Filing Overview
Filing identity: The supplied filing is Aileron Therapeutics, Inc. (Nasdaq: ALRN), not Rein Therapeutics, Inc. It is a Form 10-K for the fiscal year ended December 31, 2020, filed March 24, 2021. The summary below reflects the supplied Aileron filing.
Business Context and Reporting Period
Aileron was a clinical-stage oncology company developing ALRN-6924, an MDM2/MDMX dual inhibitor intended to protect healthy cells from chemotherapy-induced toxicities in patients with p53-mutated cancers. The company had no approved products or product sales and operated as a single business segment.
- Completed a Phase 1b trial in p53-mutated small-cell lung cancer using ALRN-6924 before topotecan.
- Continued a healthy-volunteer Phase 1 study and planned a randomized, placebo-controlled Phase 1b trial in p53-mutated non-small-cell lung cancer.
- Had eight full-time employees at December 31, 2020, including five in research and development.
Financial Performance and Liquidity
| Metric | 2020 | 2019 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $11.2 million | $17.7 million | Down $6.5 million |
| General and administrative expense | $9.3 million | $12.3 million | Down $3.0 million |
| Total operating expenses | $20.5 million | $30.0 million | Down $9.5 million |
| Loss from operations | $20.5 million loss | $30.0 million loss | Improved by $9.5 million |
| Net loss | $21.2 million | $29.4 million | Improved by $8.2 million |
| Net loss per share | $0.61 loss | $1.20 loss | Improved |
| Cash used in operating activities | $20.5 million | $26.5 million | Use decreased by $6.0 million |
- Cash, cash equivalents and investments were $13.8 million at December 31, 2020, consisting of $7.0 million of cash and cash equivalents and $6.8 million of investments. Including restricted cash, total cash, cash equivalents and restricted cash was $7.6 million.
- Accumulated deficit was $219.3 million.
- Total liabilities were $4.2 million, including a $0.4 million Paycheck Protection Program loan. The filing does not identify material conventional debt.
- Stockholders’ equity was $12.2 million, compared with $16.0 million at December 31, 2019.
- The company reported no income tax benefit because it maintained a full valuation allowance against deferred tax assets.
Material Changes Versus 2019
- Research and development spending fell primarily because earlier anti-cancer clinical programs were completed or discontinued and management narrowed ALRN-6924 development to chemoprotection. Research and development headcount declined from seven to five employees.
- General and administrative expenses declined following cost-reduction initiatives, including lower headcount-related costs, external spending and stock-based compensation.
- ALRN-6924-related research and development expense declined from $11.3 million to $7.1 million.
- Operating cash burn declined from $26.5 million to $20.5 million.
- The former headquarters lease was terminated in November 2020, resulting in a non-cash charge of approximately $0.8 million and derecognition of the related lease assets and liabilities.
- Shares outstanding increased from 27.8 million at December 31, 2019 to 43.8 million at December 31, 2020, reflecting equity financings and other issuances.
Clinical, Financial Outlook and Risks
- Management expected to initiate the NSCLC Phase 1b trial in the second quarter of 2021, report interim data at the end of 2021 and topline results in mid-2022. These are forward-looking targets, not guarantees.
- Management expected healthy-volunteer study results in mid-2021 and planned to discuss the development program with the FDA during 2021.
- Based on year-end liquidity and financing completed after year-end, management expected to fund operating expenses into the second half of 2023. The filing states that these resources would not fund all planned development or commercialization activities.
- After year-end, the company raised approximately $33.1 million net from a January 2021 registered direct offering, approximately $20.0 million net from at-the-market offerings through the filing date and approximately $2.6 million gross from the Lincoln Park equity facility.
- The company will require substantial additional financing and may raise capital through equity offerings, debt, collaborations or licensing arrangements. Additional equity financing could materially dilute existing stockholders.
- COVID-19 affected trial enrollment and delayed the healthy-volunteer study; future impacts on recruitment, trial sites, suppliers, regulatory activities and capital markets remained uncertain.
- ALRN-6924 remained an early-stage, unapproved product candidate. Positive interim Phase 1b results may not predict final or later-stage results.
- Key execution risks include patient enrollment in the p53-mutated population, regulatory approval, development of a companion diagnostic, third-party clinical and manufacturing performance, single-source API supply and competition, including FDA-approved trilaciclib.
- The company had no commercial revenue, no history of profitability and expected continuing losses.
Most Important Facts to Verify
- Confirm that the intended issuer is Aileron Therapeutics rather than Rein Therapeutics; the supplied filing does not relate to Rein Therapeutics.
- Verify the complete audited balance sheet, cash and investment balances, restricted cash and PPP loan terms.
- Reconcile the reported $13.8 million year-end cash, cash equivalents and investments with post-year-end equity proceeds and the projected cash runway into the second half of 2023.
- Review final results from the completed SCLC Phase 1b trial and distinguish interim data from audited or final clinical outcomes.
- Assess the design, enrollment, statistical endpoints and interim results of the planned NSCLC Phase 1b trial.
- Evaluate dilution from the January 2021 offering, at-the-market sales, Lincoln Park equity facility, warrants and stock options.
- Review the requirement, development status and regulatory pathway for the p53 companion diagnostic.
- Assess single-source manufacturing exposure, license obligations, patent durability and competition from trilaciclib and other chemoprotective agents.